Publications by authors named "U B Skov Sorensen"
Introduction: Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD).
Methods: Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study.
Introduction: The mechanisms leading to the conversion of atrial fibrillation (AF) to sinus rhythm are poorly understood. This study describes the dynamic behavior of electrophysiological parameters and conduction patterns leading to spontaneous and pharmacological AF termination.
Methods: Five independent groups of goats were investigated: (1) spontaneous termination of AF, and drug-induced terminations of AF by various potassium channel inhibitors: (2) AP14145, (3) PA-6, (4) XAF-1407, and (5) vernakalant.
Introduction: Obesity is associated with compromised glucose metabolism. Hence, it is of interest to investigate if the lifestyle interventions used in the LIBRA-cohort, which aimed at not only weight loss, but also patient well-being, could also help obese patients improve glucose metabolism by evidence of reduced HbA. The aim of the study was to retrospectively investigate if patients who were referred to a lifestyle intervention for obesity, were able to alter HbA.
View Article and Find Full Text PDFArticle Synopsis
- Existing antiarrhythmic drugs have limitations, and a new drug called AP30663, which targets K2 channels, showed promise in animal studies for treating atrial fibrillation (AF), but its effectiveness in humans was not yet known.
- A phase 2 trial was conducted with patients experiencing AF for 7 days or less, comparing two doses of AP30663 to a placebo, but the trial had to be halted due to slow enrollment during the COVID-19 pandemic.
- Results indicated that both doses of AP30663 led to a significant percentage of patients achieving cardioversion from AF to normal sinus rhythm within 90 minutes, with no serious adverse events linked to the drug, suggesting it could be a potential treatment
Aims: AP30663 is a novel compound under development for pharmacological conversion of atrial fibrillation by targeting the small conductance Ca activated K (K2) channel. The aim of this extension phase 1 study was to test AP30663 at higher single doses compared to the first-in-human trial.
Methods: Sixteen healthy male volunteers were randomized into 2 cohorts: 6- and 8-mg/kg intravenous single-dose administration of AP30663 vs.